eganelisib   Click here for help

GtoPdb Ligand ID: 9563

Synonyms: compound 26 [PMID: 27660692] | IPI-549 | IPI549
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Eganelisib (IPI549) is an orally bioavailable, highly selective small molecule PI3Kγ inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 124.61
Molecular weight 528.2
XLogP 5.31
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Cn1ncc(c1)C#Cc1cccc2c1c(=O)n(c(c2)C(NC(=O)c1c(N)nn2c1nccc2)C)c1ccccc1
Isomeric SMILES Cn1ncc(c1)C#Cc1cccc2c1c(=O)n(c(c2)[C@@H](NC(=O)c1c(N)nn2c1nccc2)C)c1ccccc1
InChI InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1
No information available.
Summary of Clinical Use Click here for help
IPI-549 has been advanced to phase 2 clinical evaluations, either as monotherapy or in combination with chemotherapy drugs and/or immuno-oncology agents (e.g. the anti-PD-1 checkpoint inhibitor nivolumab).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02637531 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Phase 1 Interventional Infinity Pharmaceuticals, Inc. This trial is known as the MARIO-1 study.
NCT03980041 Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2 Interventional Infinity Pharmaceuticals, Inc. Known as the MARIO-275 (MAcrophage Reprogramming in Immuno-Oncology) study, this is a global, randomized, controlled combination trial of eganelisib combined with in immuno-oncology therapy naïve urothelial cancer.
NCT03961698 Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) Phase 2 Interventional Infinity Pharmaceuticals, Inc. Known as the MARIO-3 study, this is the first eganelisib combination trial in front-line advanced cancer patients. It will evaluate IPI549 (eganelisib) in combination with and in front-line triple-negative breast cancer (TNBC) and in combination with and in front-line renal cell carcinoma (RCC).